Breaking Finance News

Robert W. Baird announced Ablynx (UNKNOWN:ABLX), raising its target price to $33.00 today

Having a price of $23.03, Ablynx (UNKNOWN:ABLX) traded 0.00% even on the day. With the last close up 0.00% from the two hundred day average, compared with the S&P 500 Index which has increased 0.01% over the same period. Ablynx has recorded a 50-day average of $0.00 and a 200-day moving average of $0.00. 0 shares of ABLX traded hands, down from an average trading volume of 0

Ablynx (UNKNOWN:ABLX) had its target bumped up to $33.00 by Robert W. Baird in an issued report announced Monday November 20, 2017. The updated stock price target implies a possible upside of 0.43% based on the company's last stock close price.

Previously on 11/10/2017, Bank of America (Merrill Lynch) released a statement for Ablynx (UNKNOWN:ABLX) bumped up the target price from $0.00 to $26.00. At the time, this indicated a possible upside of 0.24%.

Recent Performance Chart

Ablynx (UNKNOWN:ABLX)

Ablynx has one year low of $0.00 and a one year high of $0.00 and has a market capitalization of $0.

General Company Details For Ablynx (UNKNOWN:ABLX)

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-vWF Nanobody that is in Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, an anti-RSV Nanobody, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus (RSV) infection; and Vobarilizumab, an anti-IL-6R Nanobody that is in Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as auto-immune disorders; ozoralizumab, which is in a Phase IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone related disorders, including osteoporosis and bone metastases, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaborations with AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk, and Taisho Pharmaceuticals. It also has a research collaboration and licensing agreement with Sanofi for developing and commercializing Nanobody(R)-based therapeutics for the treatment of various immune-mediated inflammatory diseases. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *